ISSN: 2148-8274 / E-ISSN: 2587-0084
, Türk Üreme Tıbbı ve Cerrahisi
Dergisi

Turkish Journal of Reproductive Medicine and Surgery

Dernek Sitesi
Kayıtlı İndexler
ORİJİNAL ARAŞTIRMALAR

Progestin Primed Ovaryen Stimülasyon ve Antagonist Protokol Uygulanmış Kötü Over Yanıtlı Hastalarda Siklus Özellikleri, Elde Edilen Oosit ve Embriyo Sonuçlarının Karşılaştırılması
Comparison of Cycle Characteristics, Retrieved Oocyte and Embryo Results of Patients with Poor Ovarian Response who underwent Progestin Primed Ovarian Stimulation and Antagonist Protocols
Received Date : 26 Oct 2022
Accepted Date : 22 Dec 2022
Available Online : 27 Dec 2022
Doi: 10.24074/tjrms.2022-94028 - Makale Dili: TR
TJRMS. 2022;6(3):190-6
ÖZET
Amaç: Progestin primed ovaryen stimülasyon (PPOS) veya antagonist protokol uygulanarak kontrollü ovaryen hiperstimülasyon uygulanmış kötü over yanıtlı kadınların siklus özellikleri, oosit ve embriyo parametrelerinin retrospektif olarak karşılaştırılması. Gereç ve Yöntem: Mart 2022-Eylül 2022 tarihleri arasında Acıbadem Kozyatağı Hastanesi, Tüp Bebek Merkezi’ne infertilite nedeniyle başvurmuş hastaların dosyaları tarandı. Taranan dosyalardan PPOS (n:43) uygulanmış ve yaşları eşleştirilmiş antagonist protokol (n:93) uygulanmış, Bologna kritlerlerine göre kötü over yanıtlı kabul edilen 136 kadın çalışmaya dahil edildi. PPOS protokolünde siklusun 3. gününde günlük 10 mg medroksiprogesteron asetat, gonadotropinler ile birlikte başlanıp ovulasyon tetikleme gününe kadar devam edildi. Antagonist protokolde ise siklusun 3. gününde gonadotropinler başlandı ve önde giden folikül ortalama çapı 14 mm’ye ulaştığında günlük 0,25 mg GnRH antagonisti başlanarak ovulasyon tetikleme gününe kadar devam edildi. Kullanılan total gonadotropin dozları, stimülasyon süreleri, her iki yöntem sonucu elde edilen toplam oosit, metafaz II (M-II) oosit sayıları, maturasyon oranları, toplanan toplam oositlerin 3. ve 5. gün embriyolarına gidiş oranları gruplar arasında karşılaştırıldı. Bulgular: PPOS ve antagonist grupları arasında kullanılan toplam gonadotropin dozu (4050’ye karşı 4050, p=0,055), stimülasyon süresi (9’a karşı 10 gün, p= 0,083), toplanan toplam oosit sayısı (4’e karşı 3, p=0,523), M-II oosit sayısı (medyan değer 2’ye karşı 2, p=0,194), matürasyon oranları (%71,4’e karşı %66,7, p=0,362), toplam oositlerden 3. gün embriyo elde etme oranı (%92,7’ye karşı %91,2, p=0,721) ve toplam oositlerden 5. gün embriyo elde etme oranı (%66,7’e karşı %66,7, p=0,755) gibi siklus özellikleri ile ilgili parametreler açısından gruplar arasında fark izlenmedi. Sonuç: Antagonist preparatlarına göre daha ucuz olması ve daha kolay kullanılması (enjeksiyon yerine oral) gibi avantajlarının yanı sıra PPOS protokolü tüp bebek tedavi başarısını etkileyen önemli parametrelerde, esnek antagonist protokolü ile benzer sonuçlar vermiştir. Fertilite koruyucu amaçlarla oosit dondurma, preimplantasyon genetik tanı veya havuz yöntemi gibi taze transferin planlanmadığı durumlarda MPA ile PPOS, antagonist protokollere iyi bir alternatif olarak görünmektedir.
ABSTRACT
Objective: The aim of this retrospective cohort study was to compare the cycle characteristics, oocyte and embryo parameters of women with poor ovarian response (POR) who underwent controlled ovarian hyperstimulation (COH) using progestin primed ovarian stimulation (PPOS) or antagonist protocol. Material and Methods: This was a single-center retrospective cohort study. The records of women with POR (defined by the Bologna criteria) who applied to Acibadem Kozyatagi Hospital, IVF center between March and September 2022 were evaluated. 43 women who underwent PPOS and 93 age-matched women who underwent antagonist protocol were included to our study. In the PPOS protocol, medroxyprogesterone acetate (MPA) 10 mg/daily was started along with gonadotropins at the 3rd day of cycle and continued until ovulation trigger day. In the antagonist protocol, gonadotropins were started at the 3rd day of cycle and daily 0,25 mg GnRH antagonist injections were started when the mean follicular diameter of the leading follicle reached 14 mm and continued until ovulation trigger day. Total gonadotropin doses, duration of stimulation, number of total oocytes, metaphase II (M-II) oocytes, maturation rates, rates of total oocytes reaching day 3 and 5 embryos were compared between two groups. Results: There was no significant difference regarding total gonadotropin use (4050 vs. 4050, p=0,055), duration of stimulation (9 vs. 10 days, p= 0,083), number of total oocytes retrieved (4 vs. 3, p=0,523), number of M-II oocytes (median value 2 vs. 2, p=0,194), maturation rates (71,4% vs. 66,7%, p=0,362), rate of total oocytes reaching day 3 embryos (92,7% vs. 91,2%, p=0,721) and rate of total oocytes reaching day 5 embryos (66,7% vs. 66,7%, p=0,755) between PPOS and antagonist groups. Conclusion: In addition to its advantages such as being cheaper and easier to use (oral instead of injections) compared to antagonists, the PPOS protocol provided similar results with flexible antagonist protocol regarding important parameters affecting the success of IVF treatments. In cases like oocyte cryopreservation, preimplantation genetic testing and embryo pooling where fresh embryo transfer is not aimed, PPOS with MPA seems like a good alternative to flexible antagonist protocol.
REFERANSLAR
  1. Depalo R, Jayakrishan K, Garruti G, Totaro I, Panzarino M, Giorgino F, et al. GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). Reprod Biol Endocrinol. 2012;10:26. [Crossref]  [PubMed]  [PMC] 
  2. La Marca A, Capuzzo M. Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Reprod Biomed Online. 2019;39(2):321-31. [Crossref]  [PubMed] 
  3. Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104(1):62-70.e3. [Crossref]  [PubMed] 
  4. Yu S, Long H, Chang HY-N, Liu Y, Gao H, Zhu J, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018;33(2):229-37. [Crossref]  [PubMed] 
  5. Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017;23(2):211-20. [Crossref]  [PubMed] 
  6. Yildiz S, Turkgeldi E, Angun B, Eraslan A, Urman B, Ata B. Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology. Fertil Steril. 2019;112(4):677-83. [Crossref]  [PubMed] 
  7. Turkgeldi E, Yildiz S, Cekic SG, Shakerian B, Keles I, Ata B. Effectiveness of the flexible progestin primed ovarian stimulation protocol compared to the flexible GnRH antagonist protocol in women with decreased ovarian reserve. Hum Fertil (Camb). 2022;25(2):306-12. [Crossref]  [PubMed] 
  8. Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial. Medicine (Baltimore). 2016;95(9): e2939. [Crossref]  [PubMed]  [PMC] 
  9. Ferraretti AP, La Marca A, Fauser BCJM, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of "poor response" to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616-24. [Crossref]  [PubMed] 
  10. Dong J, Wang Y, Chai WR, Hong QQ, Wang NL, Sun LH, et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG. 2017;124(7):1048-55. [Crossref]  [PubMed] 
  11. Cimadomo D, Vaiarelli A, Colamaria S, Trabucco E, Alviggi C, Venturella R, et al. Luteal phase anovulatory follicles result in the production of competent oocytes: intra-patient paired case-control study comparing follicular versus luteal phase stimulations in the same ovarian cycle. Hum Reprod. 2018;33(8):1442-8. [Crossref]  [PubMed]  [PMC] 
  12. Ubaldi FM, Capalbo A, Vaiarelli A, Cimadomo D, Colamaria S, Alviggi C, et al. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril. 2016;105(6):1488-95.e1. [Crossref]  [PubMed] 
  13. Kuang Y, Hong Q, Chen Q, Lyu Q, Ai A, Fu Y, et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014;101(1):105-11. [Crossref]  [PubMed] 
  14. Chen Q, Chai W, Wang Y, Cai R, Zhang S, Lu X, et al. Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing in vitro Fertilization Treatment: A Randomized Controlled Trial. Front Endocrinol (Lausanne). 2019;10:796. [Crossref]  [PubMed]  [PMC] 
  15. Chen Y-M, Qi Q-R, Xie Q-Z, Yang Y-F, Xia Y, Zhou X-D. Effect of Progestin-primed Ovarian Stimulation Protocol on Outcomes of Aged Infertile Women Who Failed to Get Pregnant in the First IVF/ ICSI Cycle: A Self-controlled Study. Curr Med Sci. 2018;38(3):513-8. [Crossref]  [PubMed] 
  16. Kao T-C, Hsieh Y-C, Yang I-J, Wu M-Y, Chen M-J, Yang J-H, et al. Progestin-primed ovarian stimulation versus GnRH antagonist protocol in poor responders: Risk of premature LH surge and outcome of oocyte retrieval. J Formos Med Assoc. 2022. [Crossref]  [PubMed] 
  17. Lin H-T, Wu M-H, Tsai L-C, Chen T-S, Ou H-T. Co-Administration of Clomiphene Citrate and Letrozole in Mild Ovarian Stimulation Versus Conventional Controlled Ovarian Stimulation Among POSEIDON Group 4 Patients. Front Endocrinol (Lausanne). 2021;12:780392. [Crossref]  [PubMed]  [PMC] 
  18. Doğan Durdağ G, Bektaş G, Türkyılmaz E, Göktepe H, Sönmezer M, Şükür YE, et al. The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation. J Turkish Ger Gynecol Assoc. 2021;22(4):293-9. [Crossref]  [PubMed]  [PMC] 
  19. Kalafat E, Dizdar M, Turkgeldi E, Yildiz S, Keles I, Ata B. The Comparison of Fixed and Flexible Progestin Primed Ovarian Stimulation on Mature Oocyte Yield in Women at Risk of Premature Ovarian Insufficiency. Front Endocrinol (Lausanne). 2021;12:797227. [Crossref]  [PubMed]  [PMC] 
  20. Zhang J, Du M, Li Z, Liu W, Ren B, Zhang Y, et al. Comparison of Dydrogesterone and Medroxyprogesterone in the Progestin-Primed Ovarian Stimulation Protocol for Patients With Poor Ovarian Response. Front Endocrinol (Lausanne). 2021;12:708704. [Crossref]  [PubMed]  [PMC]